biogen - Search News

Eisai, Biogen and CHMP

Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.

Reuters · 3d

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review.

Business Insider · 4d

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA,

MarketWatch · 4d

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

The companies on Friday said the European Commission, which had asked the panel to consider information on the safety of Leqembi that became available after it adopted a positive opinion in November,

Reuters on MSN · 4d

EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.

Biogen (BIIB) Receives a Hold from Piper Sandler

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

15h

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

20don MSN

Drugmaker Biogen forecasts 2025 profit below expectations

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Investors sold Biogen shares in 2024 ...

STAT13d

Biogen partners with Stoke Therapeutics on drug for severe epilepsy

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

13d

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.